Becton Dickinson & Co. recalled 177 units of the BD BACTEC Blood Culture System on September 23, 2025. Unauthorized access to product service credentials poses a high risk to patient data and device integrity. Healthcare providers must stop using the devices immediately and follow recall instructions.
Product service credentials used by some BD technical support teams to access certain BD products were accessed by an unauthorized actor. Until these product service credentials are updated, there is a risk of unauthorized access that may impact the confidentiality, integrity and/or availability of the relevant products and associated data.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Becton Dickinson & Co. or your healthcare provider for instructions. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The recall involves several models, including the BD BACTEC FX (Catalog Number: 44138509) and BACTEC 9240 System (Catalog Number: 445569). These products were distributed worldwide, including the U.S., Canada, and multiple countries across Europe and Asia.
Unauthorized access to product service credentials raises concerns about the confidentiality and integrity of patient data. This breach poses a significant risk to the security of the relevant products and associated data.
There are no specific reported injuries or incidents related to this breach. However, the potential for unauthorized access constitutes a serious risk.
Stop using the BD BACTEC Blood Culture System immediately. Contact Becton Dickinson & Co. or your healthcare provider for further instructions.
For more information, contact Becton Dickinson & Co. at their official website or by phone. Detailed instructions are also available via the FDA recall announcement.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.